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Summary
Background Phosphodiesterase-5 (PDE5) inhibitors improve exercise capacity and quality of life in patients with 
idiopathic pulmonary arterial hypertension. However, whether such beneﬁ cial eﬀ ects take place in selected populations 
with chronic obstructive pulmonary disease (COPD) remains uncertain. We aimed to assess the eﬀ ects of tadalaﬁ l—a 
PDE5 inhibitor—on exercise capacity and quality of life in patients with COPD and mild pulmonary hypertension.
Methods We did a randomised, double-blind, parallel-group, placebo-controlled trial at three centres in Scotland, UK, 
between Sept 1, 2010, and Sept 1, 2012. Patients with moderate to severe COPD were randomly assigned (1:1), via 
centralised randomisation with a computer-generated sequence and block sizes of four, to receive daily tadalaﬁ l 10 mg 
or placebo for 12 weeks. Patients, study investigators, outcome assessors, and those administering drugs were masked 
to group allocation. The primary endpoint was the mean placebo-corrected diﬀ erence between the baseline and ﬁ nal 
6 min walk distance after 12 weeks. We measured change in quality of life at baseline, 8 weeks, and 12 weeks, with 
standardised questionnaires. Analysis was per protocol and by intention to treat. This trial is registered with 
ClinicalTrials.gov, number NCT01197469.
Findings 120 patients were randomly assigned to receive tadalaﬁ l (n=60) or placebo (n=60), of whom 56 (93%) 
versus 57 (95%) completed the study. At 12 weeks the diﬀ erence in 6 min walking distance between the tadalaﬁ l 
and placebo groups was 0·5 m (95% CI –11·6 to 12·5; p=0·937). We recorded no statistically signiﬁ cant changes 
in quality of life (between-group diﬀ erence on the St George’s Respiratory Questionnaire –2·64 
[95% CI –6·43 to 1·15]; Research and Development version 1 short-form-36 4·08 [–1·35 to 9·52]; Minnesota 
Living with Heart Failure questionnaire –2·31 [–7·06 to 2·45]). 19 (32%) of 60 patients in the treatment group 
had dyspepsia; the severity of dyspepsia ranged from mild to severe, with four (21%) of 19 patients needing a 
proton-pump inhibitor. Five (8%) of 60 participants had dyspepsia in the placebo group. Headache was noted in 
17 (28%) patients in the treatment group versus 5 (8%) in the placebo group, but was mild in all patients. Two 
(3%) patients in the treatment group had facial ﬂ ushing, which resulted in one withdrawal. Other withdrawals 
within the tadalaﬁ l group happened after a transient ischaemic attack and two deaths (ruptured abdominal aortic 
aneurysm and pneumonia).
Interpretation Tadalaﬁ l does not improve exercise capacity or quality of life despite exerting pulmonary vasodilation.
Funding Chief Scientist Oﬃ  ce for Scotland.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major 
cause of mortality and morbidity worldwide. Pulmonary 
vascular disease happens early in the natural history of 
COPD, when pulmonary vascular changes have been 
reported in cigarette smokers with normal spirometry 
values.1 Pulmonary arterial vasoconstriction, vessel-wall 
hypertrophy, and loss of pulmonary blood vessels 
contribute to the burden of pulmonary vascular disease, 
resulting in the development of pulmonary hypertension.
 COPD-associated pulmonary hypertension reduces 
exercise tolerance2 and quality of life. Modest increases in 
pulmonary arterial pressure, that are less than the cutoﬀ  
considered to represent pulmonary hypertension, can 
strongly predict mortality3 and risk of hospital admission 
during an exacerbation.4 In patients with COPD without 
pulmonary hypertension (mean pulmonary artery 
pressure <25 mm Hg), or with borderline hypertension 
(21–25 mm Hg), these slight changes in pulmonary 
arterial pressure are associated with impaired right 
ventricular systolic function, hypertrophy, and dilatation,5 
changes that are increasingly present as the severity of 
pulmonary vascular disease worsens. Furthermore 
pulmonary arterial pressures frequently rise abnormally 
during activities of daily living, even in individuals without 
resting pulmonary hypertension.6 Although severe, or so-
called dis proportionate, pulmonary hypertension in 
patients with low-severity airway obstruction does take 
place in patients with COPD, it is uncommon 
(<5% prevalence),7 possibly representing the coexistence 
of idiopathic pulmonary arterial hypertension.
Phosphodiesterase-5 (PDE5) inhibitors are pulmonary 
arterial vasodilator drugs that are used to treat pulmonary 
hypertension, supported by evidence that they improve 
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exercise capacity and quality of life.8 Although 
sildenaﬁ l—a short-acting PDE5 inhibitor—can improve 
pulmonary haemodynamics at rest and during exercise 
in patients with COPD-associated pulmonary hyper-
tension,9 whether pulmonary arterial vasodilation 
improves exercise capacity and quality of life has not 
been established. Concerns about the potential for 
clinical worsening remain on the basis of the use of other 
pulmonary vasodilator drugs, such as bosentan in 
unselected populations with severe COPD and sildenaﬁ l 
in patients with severe COPD with emphysema, but 
without pulmonary hypertension.10,11 In both studies, 
deleterious eﬀ ects were reported on quality of life, with 
no beneﬁ cial eﬀ ect on exercise capacity. We postulated 
that treatment with tadalaﬁ l—a long-acting PDE5 
inhibitor—would improve exercise capacity and quality 
of life in selected patients with COPD and mild 
pulmonary hypertension.
Methods
Study design and patients  
We undertook this randomised, double blind, parallel-
group, placebo-controlled trial at three centres in 
Scotland, UK (Dundee, Perth, and Fife) between Sept 1, 
2010, and Sept 1, 2012. We recruited patients with COPD 
via a network of pulmonary physiotherapists, respiratory 
consultants, and family doctors covering two UK 
National Health Service boards (Tayside and Fife) where 
potential candidates were identiﬁ ed through COPD 
databases.
Panel 1 shows the study eligibility criteria. All patients 
were smokers or ex-smokers with a diagnosis of COPD 
conﬁ rmed according to American Thoracic Society and 
European Respiratory Society criteria, a post-broncho-
dilator forced expiratory volume in 1 s (FEV1) less than 
80%, and an FEV1 to forced vital capacity ratio of less 
than 70%.12 The echocardiographic inclusion criteria 
signify values beyond the normal range (ie, pulmonary 
acceleration time <120 ms or right ventricular systolic 
pressure >30 mm Hg). Participants had had no 
exacerbation of COPD for at least 1 month at study entry. 
All regularly prescribed COPD drugs were continued. All 
patients provided written informed consent. Ethics 
approval was obtained from the North Research Ethics 
Committee (reference 10/S0801/46).
Randomisation and masking  
Eligible patients were randomly assigned in a 1:1 ratio, 
via centralised randomisation with a computer-generated 
sequence and block sizes of four, to receive daily tadalaﬁ l 
10 mg or matched placebo, orally. The intervention and 
placebo packs were identical in presentation (capsules 
and bottle) and double blinding was maintained 
throughout. Patients, study investigators, outcome 
assessors, and those administering drugs were masked 
to group allocation. Unmasking was done only after the 
end of the trial once all data had been collected and 
analysed.
Procedures  
We used a MicroLoop spirometer to establish COPD 
diagnoses (Micro Medical, Rochester, UK). ARG 
undertook echocardiographs with a Philips iE33 system 
(Philips, The Netherlands) for participants from Dundee, 
and the Siemens Acuson CV70 (Siemens AG Medical 
Figure 1: Trial proﬁ le
*Ruptured abdominal aortic aneurysm; ventilator-associated pneumonia after exacerbation of chronic obstructive 
pulmonary disease. †Admitted to hospital.
1908 participants invited
432 positive responses
1476 not interviewed
 394 negative responses
 1082 did not reply
4 withdrawn
 1 transient ischaemic attack
 1 severe facial flushing
 2 deaths*
279 screened
153 unsuitable or not needed
120 randomised
60 assigned to tadalafil
3 withdrawn
 1 had postural hypotension 
  with falls†
 1 myocardial infarction
 1 painful peripheries and finger 
  ulceration
60 assigned to placebo
56 completed 57 completed
159 ineligible
Panel 1: Inclusion and exclusion criteria
Inclusion criteria
• Male or female participants, aged between 35 and 
85 years inclusive
• Known diagnosis of chronic obstructive pulmonary disease
• A post-bronchodilator forced expiratory volume in 1 s 
<80% predicted
• Pulmonary acceleration time <120 ms or right ventricular 
systolic pressure >30 mm Hg
Exclusion criteria
• Pulmonary stenosis
• Left-ventricular outﬂ ow obstruction conﬁ rmed by 
echocardiography
• Left-ventricular systolic dysfunction (<45%)
• Patients taking nitrates, nicorandil, or doxazosin
• Systolic blood pressure < 90 mm Hg, recent stroke, unstable 
angina, past history of non-arteritic anterior ischaemic optic 
neuropathy
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Solutions, Germany) for those from Perth and Fife. In 
addition to standard acoustic windows, we used an 
oblique subcostal window to assess the pulmonary 
acceleration time and the right-ventricular ejection time 
with pulse-wave Doppler, as previously described.13 We 
then calculated estimated mean pulmonary arterial 
pressure with the Dabestani equation,13,14 and right 
ventricular systolic pressure with the Bernoulli equation. 
We estimated right atrial pressure on the basis of the size 
and collapsibility of the inferior vena cava.15 We measured 
the thickness of the right ventricle (subcostal window 
acquisition) and the function (tricuspid annular plane 
systolic excursion) with a standard operating procedure.15 
We qualitatively assessed the presence of dilatation of the 
right ventricle. Exercise capacity was limited by exertional 
breathlessness in all participants.
If eligibility criteria were met, patients were given a 
50 mg test dose of sildenaﬁ l and observed for 3 h. Resting 
and postural blood pressure and pulse oximetry (SpO2) 
were measured at baseline, and at 30, 60, 120, and 
180 min. Partcipants were randomised if they were free 
from clinically signiﬁ cant symptoms, hypotension 
(systolic blood pressure <90 mm Hg) or symptomatic 
postural hypotension (a decrease of ≥20 mm Hg in 
systolic blood pressure drop during 3 min of standing) 
throughout the test dose observation period. Cor-
respondence with family doctors, safety cards, and 
warning stickers on paper notes minimised the risk of 
clinically signiﬁ cant hypotension through inadvertent 
prescription of nitrate-containing drugs.
The 6 min walk test was done at baseline, and at 
weeks 8 and 12, on a ﬂ at, straight, 30 m course with use 
of standardised encouragement.16 Two walks were 
undertaken 1 h apart. Patients were allowed to use their 
usual walking aids but oxygen was not permitted. We 
assessed quality of life at baseline, 8 weeks, and 12 weeks 
with standardised questionnaires. The St George’s 
Respiratory Questionnaire identiﬁ es how breathing 
problems aﬀ ect patients’ lives scored on a scale of 0 
(no impairment) to 100 (maximum impairment). The 
Research and Development version 1 short-
form-36 questionnaire measures functional health and 
well-being scores within 8 domains, scored from 0 to 
100 whereby higher scores represent better function. The 
Minnesota Living with Heart Failure questionnaire has 
been validated for pulmonary hypertension17 whereby 
higher scores reﬂ ect worse quality of life. We measured 
SpO2 at the beginning and end of the walk test and at any 
temporary stops that were needed because of severe 
exertional dyspnoea. B-natriuretic peptide, high-
sensitivity C-reactive protein, and spirometry were also 
measured at baseline, and at weeks 8 and 12. The single-
breath diﬀ using capacity of the lung was done in 
accordance with the American Thoracic Society and 
European Respiratory Society task force guidelines18 at 
baseline and 12 weeks (Sensormedics Vmax 229, 
SensorMedics Corporation, USA [Dundee and Perth]; 
Morgan Pulmolab TT 501, Morgan Medical Ltd, UK 
[Fife]). Echo cardio graphy was done at baseline and 
12 weeks. Two additional safety visits and telephone 
consultations were organised around the main visits. 
Adverse events were logged and capsules were counted at 
all visits to assess compliance. Blood pressure and SpO2 
were measured at all visits.
Outcomes  
The primary outcome was the mean placebo-corrected 
diﬀ erence between the baseline and ﬁ nal 6 min walk 
distance after 12 weeks of tadalaﬁ l. Secondary measures 
were change in quality of life, cardiac stress 
(B-natriuretic peptide), systemic inﬂ ammation (high-
sensitivity C-reactive protein), lung diﬀ usion (single-
breath diﬀ using capacity), lung function (spirometry), 
and cardiac function (echocardiography).
Statistical analysis  
The primary objective was to establish whether tadalaﬁ l 
would improve exercise capacity in patients with COPD. 
Other work in this specialty suggests that a 54 m increase 
in 6 min walking distance should be regarded as the 
minimum clinically important distance at which patients 
Tadalaﬁ l (n=60) Placebo (n=60)
Age (years) 68 (8) 70 (7)
Men 42 (70%) 40 (67%)
BMI (kg/m2) 26·7 (5·3) 25·7 (5·1)
MRC dyspnoea scale 3·4 (0·9) 3·4 (1·0)
Pack-year history 49·7 (23·0) 47·3 (18·8)
BODE index 4·4 (2·3) 4·3 (2·5)
FEV1(L)*† 1·1 (0·4) 1·0 (0·5)
FEV1 (%)*† 41 (14·0) 40 (17·0)
Pulmonary acceleration time (ms) 98 (10·0) 97 (13·0)
Mean pulmonary arterial pressure (mm Hg)‡ 30 (5·0) 31 (7·0)
Right ventricular systolic pressure (mm Hg) 42 (9·0) 42 (10·0)
SpO2 95·4 (3·0) 95·3 (2·8)
B-natriuretic peptide (pg/mL) 19·6 (9–46) 24·5 (12–50)
hs-CRP (mg/L) 2·92 (1·46–4·98) 2·64 (1·31–5·47)
Adjusted DLCO (%)* 40·9% (14·4) 34·7% (12·0)
Baseline 6MWD (m) 354 (105) 341 (104)
Bicarbonate (mmol/L) 26·6 (0·4) 26·7 (0·4)
Right ventricular hypertrophy (mm) 6·6 (0·2) 6·5 (0·2)
Right ventricular dilatation 17 (28%) 17 (28%)
TAPSE (mm) 22 (4·0) 21 (4·0)
Diabetes mellitus 3 (5%) 7 (12%)
Ischaemic heart disease 4 (7%) 5 (8%)
Cerebrovascular disease 7 (12%) 2 (3%)
Chronic kidney disease 7 (12%) 4 (7%)
Data are mean (SD), n (%), or median (IQR), unless otherwise indicated. BMI=body-mass index. MRC=modiﬁ ed 
research council. FEV1= forced expiratory volume in 1 sec. SpO2=blood oxygen saturation. hs-CRP=high-sensitivity 
C-reactive protein. DLCO=diﬀ usion of lung carbon monoxide. 6MWD=6 min walking distance. TAPSE=tricuspid 
annular plane systolic excursion. *Litres and percentage predicted. †Post-bronchodilator. ‡Dabestani equation.
Table 1: Baseline characteristics
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consider themselves to feel subjectively better.19 From 
the available literature we ascertained that a mean 6 min 
walking distance in patients with severe COPD would be 
roughly 285 m (SD 96).20 A sample size of 104 patients 
was needed to achieve 80% power at a 5% signiﬁ cance 
level. We increased the number to 120 to account for 
dropouts. We present data as means with SDs for 
continuous variables, and as numbers with percentages 
for categorical variables. For the primary outcome, we 
analysed data with the student’s t test to identify the 
mean diﬀ erence between groups at 12 weeks. Further-
more, a general linear model with repeated measures for 
multiple time points (ANOVA) was done with a post-hoc 
Bonferroni correction to avoid confounding of the 
overall α error in the two groups. We used a paired t test 
to test the diﬀ erences within groups in data at baseline 
and 12 weeks. For the secondary outcome, we used the 
student’s t test to examine the diﬀ erences between the 
two groups. For non-normally distributed data we used 
the Mann-Whitney U test. We used the χ2 test to assess 
the diﬀ erences in categorical variables between the two 
groups. Primary analysis was per protocol, with a 
separate intention-to-treat analysis done with multiple 
imputation to address missing data.
No interim analysis was done. Analysis was done mainly 
on completers, with additional sensitivity analysis, and 
used data for the best walk test for each patient. Data 
analysis was independently veriﬁ ed by the study 
statistician. This trial is registered with ClinicalTrials.gov, 
number NCT01197469.
Role of the funding source
The Chief Scientist Oﬃ  ce for Scotland (CZB/4/666) 
solely funded the study, with no role in the writing and 
ﬁ nal decision to submit for publication. Our sponsor was 
the University of Dundee who had no role in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. ARG and PJH had full access to 
the all the data in the study and ARG had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. 120 patients were 
randomly assigned to receive tadalaﬁ l (n=60) or placebo 
(n=60), of whom 113 (94%) completed the study. Baseline 
characteristics were similar between groups (table 1). 
Patients had severe COPD and borderline to mild 
pulmonary hypertension with a moderate impairment of 
diﬀ usion capacity (table 1). The upper range for right 
ventricular systolic pressure was 81 mm Hg and the lower 
range for pulmonary acceleration time was 69 ms 
(estimated mean pulmonary arterial pressure 47 mm 
Hg). Right ventricular thickness was measurable at 
baseline in 114 (95%) of 120 patients. 108 (90%) patients 
had echocardiographic evidence of right ventricular 
hypertrophy (≥5 mm right ventricular  free wall 
thickness). In the 89 patients in whom tricuspid annular 
plane systolic excursion could be measured, 86 (97%) had 
preserved right ventricular function. The high proportion 
of patients prescribed combination inhaled corticosteroid 
and long-acting β agonists (109 [91%]) and long-acting 
muscarinic antagonists (104 [87%]) was typical of a 
moderate to severe cohort with COPD. 13 (11%) patients 
were receiving long-term oxygen therapy and 16 (13%) 
were receiving a loop diuretic. 79 (66%) patients had 
exercise desaturation (≥4% decrease in SpO2). No patients 
had a history of thromboembolic disease or were receiving 
anticoagulants.
In the  per-protocol analysis, the placebo-corrected 
diﬀ erence in 6 min walking distance after 12 weeks of 
tadalaﬁ l was 0·5 m (95% CI –11·6 to 12·5; p=0·937 
Tadalaﬁ l
(n=56)
Placebo
(n=57)
Absolute diﬀ erence p 
value
SGRQ*
Total score –1·00 (–3·57 to 1·56) 1·64 (–1·20 to 4·48) –2·64 (–6·43 to 1·15) 0·170
Symptoms score 1·76 (–3·00 to 6·51) –1·64 (–8·09 to 4·81) 3·40 (–4·54 to 11·33) 0·398
Activity score –1·87 (–5·38 to 1·64) 2·54 (–0·80 to 5·88) –4·41 (–9·20 to 0·38) 0·071
Impacts score† –1·39 (–4·20 to 1·42) 2·12 (–1·01 to 5·25) –3·51 (–7·68 to 0·66) 0·098
SF-36‡
Physical functioning 2·68 (–1·36 to 6·72) –1·40 (–5·14 to 2·33) 4·08 (–1·35 to 9·52) 0·139
Pain 0 (–10 to 10) 0 (–16·25 to 16·25) ·· 0·365
General health 0 (–5 to 5) 0 (–7·5 to 7·5) ·· 0·559
Emotional well-being 0 (–4 to 8) 0 (–10 to 8) ·· 0·233
Physical role limitations 0 (0 to 0) 0 (–0 to 12·5) ·· 0·775
Emotional role limitations 0 (0 to 0) 0 (0 to 0) ·· 0·931
Social functioning 0 (–12·5 to 12·5) 0 (–12·5 to 12·5) ·· 0·997
Energy or fatigue 0 (–10 to 10) 0 (–10 to 10) ·· 0·577
MLHFQ*
Total –0·57 (–3·18 to 2·03) 1·74 (–2·28 to 5·75) –2·31 (–7·06 to 2·45) 0·338
Physical –0·14(–1·68 to 1·39) 0·61 (–1·21 to 2·43) –0·76 (–3·12 to 1·60) 0·527
Emotional –0·39 (–1·09 to 0·31) 0·30 (–1·17 to 1·77) –0·69 (–2·31 to 0·93) 0·398
Data are mean (95% CI) or median (IQR), unless otherwise indicated. SGRQ=St George’s Respiratory Questionnaire. 
SF-36=Short Form (36) Health Survey (RAND version 1). MLHFQ=Minnesota Living with Heart Failure Questionnaire. 
*Negative scores show improvement in quality of life. †Social function ‡Higher score reﬂ ects better quality of life.
Table 2: Mean change in quality-of-life scores at 12 weeks compared with baseline
Figure 2: Mean change in 6MWD between groups over time
Error bars 95% CIs. 6MWD=6 min walking distance.
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(ﬁ gure 2). In the intention-to-treat population the 
diﬀ erence was –1·3 m (–6·2 to 3·6; p=0·595). The 
adjusted analysis for baseline walking distance 
(ANCOVA) was 0·5 m (–11·7 to 12·6; p=0·934). We noted 
signiﬁ cant mean changes of 15·5 m (6·8–24·2; 
p=0·0007) in the tadalaﬁ l group and 15·0 m (6·5–23·6; 
p=0·0009) in the placebo group after 12 weeks compared 
with at baseline. Repeated measures ANOVA conﬁ rmed 
signiﬁ cant diﬀ erences over time in both the tadalaﬁ l 
(p=0·001) and placebo groups (p=0·003). In a 
prespeciﬁ ed analysis, we analysed good walkers (≥285 m; 
n=88) and poor walkers (<285 m; n=23) separately. No 
signiﬁ cant diﬀ erences in 6 min walking distance were 
shown between groups during the 12 weeks in both good 
walkers (mean diﬀ erence –0·2 m, 95% CI –13·5 to 13·1; 
p=0.978) and poor walkers (7·5 m, –23·6 to 38·5; 
p=0·623). Furthermore, no signiﬁ cant changes were 
shown in the degree of exertional breathlessness during 
the 6 min walking test (p=0·714; data not shown). 
Conclusions were unchanged in further sensitivity 
analysis in patients with right-ventricular dilatation 
(n=26, mean diﬀ erence 20·5 m, 95% CI –10·4 to 51·4; 
p=0·184), the lowest (worst) pulmonary acceleration 
times (n=60, –6·0 m, –24·2 to 12·1; p=0·507), and the 
highest FEV1 at baseline (n=58, 1·0 m, –16·5 to 18·6; 
p=0·905).
We recorded no statistically signiﬁ cant changes in any 
of the quality-of-life measures (table 2).
Table 3 provides echocardiographic data. On the basis 
of the mean pulmonary arterial pressure derived from 
pulmonary acceleration time, 114 (96%) of patients had a 
pressure of more than 20 mm Hg and 94 (79%) had a 
pressure of more than 25 mm Hg. We measured 
tricuspid annular plane systolic excursion in all patients 
when technically feasible (n=73). Data for right 
ventricular systolic pressure were limited to 25 patients 
in whom such data could be measured at both the start 
and the end of study. No statistically signiﬁ cant changes 
were noted in spirometry, diﬀ using capacity of the lung, 
B-natriuretic peptide, or high-sensitivity C-reactive 
protein (table 4). At 12 weeks, 49 (41%) patients had had 
an exacerbation of COPD. The frequency of exacerbations 
Tadalaﬁ l (n=56) Placebo (n=57) Mean diﬀ erence 
between groups 
(95% CI)
p value*
n (%) Initial Final n (%) Initial Final
PAT (ms) 55 
(98%)
97·7 (9·9) 106·3 (12·8) 56 
(98%)
97·0 (12·9) 98·3 (15·8) 7·3 (0·9 to 13·6) 0·001
mPAP (mm Hg)† 55 
(98%)
30·1 (5·2) 26·6 (5·2) 56 
(98%)
30·8 (6·8) 30·8 (7·5) –3·5 (–6·6 to –0·4) 0·025
PAT/RVET 55 
(98%)
0·36 (0·08) 0·39 (0·05) 56 
(98%)
0·37 (0·06) 0·37 (0·06) 0·02 (0·01 to 0·04) 0·008
RVSP (mm Hg) 12 
(21%)
43·5 (9·5) 38·8 (10·3) 13 
(23%)
43·9 (10·9) 51·5 (15·6) –12·3 (–20·9 to –3·6) 0·007
TAPSE (mm) 37 
(66%)
21·3 (3·7) 22·1 (4·1) 36 
(63%)
21·1 (3·5) 20·8 (4·4) 1·1 (–1·1 to 3·3) 0·319
Data are mean (SD), unless otherwise indicated. PAT=pulmonary acceleration time. mPAP=mean pulmonary arterial pressure. PAT/RVET=ratio of pulmonary acceleration 
time to right ventricular ejection time. RVSP=right ventricular systolic pressure. TAPSE=tricuspid annular plane systolic excursion. *From two independent samples t tests. 
†Derived, based on Dabestani’s equation.
Table 3: Echocardiographic parameters after 12 weeks by treatment group
Tadalaﬁ l (n=56) Placebo (n=57) Mean diﬀ erence 
between groups 
(95% CI)
p value*
n (%) Initial Final n (%) Initial Final
B-natriuretic peptide (pg/mL)† 56 (100%) 1·29 (0·42) 1·32 (0·45) 57 (100%) 1·42 (0·44) 1·44 (0·48) 0·01 (–0·09 to 0·12) 0·844
hs-CRP (mg/L)† 56 (100%) 0·49 (0·47) 0·58 (0·52) 57 (100%) 0·47 (0·43) 0·53 (0·49) 0·03 (–0·12 to 0·18) 0·722
Adjusted DLCO (%)‡ 56 (100%) 40·9 (15·2) 41·2 (16·4) 56 (98%) 35·1 (12·1) 34·2 (11·2) 0·85 (–1·46 to 3·16) 0·469
FEV1 (L) 56 (100%) 1·08 (0·38) 1·05 (0·38) 57 (100%) 1·01 (0·43) 0·99 (0·40) –0·02 (–0·07 to 0·03) 0·420
FEV1 (%)§ 56 (100%) 41·4 (14·7) 40·1 (15·4) 57 (100%) 39·5 (16·2) 38·9 (15·2) –0·50 (–2·5 to 1·5) 0·615
Forced vital capacity (L) 56 (100%) 2·88 (0·8) 2·86 (0·77) 57 (100%) 2·74 (0·99) 2·82 (0·99) 0·22 (–0·42 to 0·85) 0·502
Forced vital capacity (%)§ 56 (100%) 85·6 (18·4) 85·4 (19·9) 57 (100%) 83·5 (23·6) 84·9 (22·5) –2·4 (–6·5 to 1·7) 0·250
Data are mean (SD), unless otherwise indicated. hs-CRP=high-sensitivity C-reactive protein. DLCO=diﬀ usion capacity of lung for carbon monoxide. FEV1=forced expiratory volume 
in 1 s. *From two independent samples t tests. †Log10 for parametric testing; ‡Adjusted for haemoglobin, expressed as percentage of predicted value. §Percentage predicted.
Table 4: Secondary outcomes before and after 12 weeks of treatment by group
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was higher in patients in the the placebo group than in 
those in the tadalaﬁ l group (27 [45%] vs 22 [37%]; 
p=0·609). Four (7%) patients in the placebo group were 
admitted to hospital during an exacerbation of COPD 
versus three (5%) patients in the treatment group.
Compliance was high (107 [95%] of 113 completers). 
Common side-eﬀ ects of tadalaﬁ l were reported (data not 
shown). With the exception of dyspepsia and headache, 
all side-eﬀ ects were transient in nature (data not 
shown). 19 (32%) of 60 patients in the tadalaﬁ l group 
had dyspepsia compared with ﬁ ve (8%) of 60 patients in 
the placebo group. The severity of dyspepsia ranged 
from mild to severe with four (21%) of 19 patients 
needing a proton-pump inhibitor. Headache was noted 
in 17 (28%) patients in the tadalaﬁ l group versus ﬁ ve 
(8%) in the placebo group, but was mild in all patients 
(data not shown). Two (3%) patients in the tadalaﬁ l 
group had facial ﬂ ushing, which resulted in one 
withdrawal. Other withdrawals within the tadalaﬁ l 
group happened after a transient ischaemic attack and 
two deaths (ruptured abdominal aortic aneurysm and 
pneumonia).
After one 50 mg dose of oral sildenaﬁ l we noted a 
signiﬁ cant reduction in resting SpO2 of 2·2% (95% CI 
1·6–2·7; p<0·0001; ﬁ gure 3. Despite this decrease, only 
one patient described a transient increase in 
breathlessness versus two patients who felt less 
breathless. 60 min after receiving the sildenaﬁ l, the 
mean systolic blood pressure reduced maximally by 
15·6 mm Hg (11·1–20·0; p<0·0001). Five patients had 
symptomatic postural hypotension during the test dose 
and were therefore ineligible for randomisation. 
Chronic dosing with tadalaﬁ l at 10 mg once daily did 
not result in any signiﬁ cant diﬀ erences between group 
in SpO2 at 12 weeks, with a mean change of –0·91% (SD 
1·6) in the tadalaﬁ l group and –0·70% (2·0) in the 
placebo group (p=0·543). We recorded no signiﬁ cant 
group diﬀ erences in blood pressure (data not shown). 
No patients receiving long-term oxygen therapy needed 
an increase in oxygen dose and no new prescriptions of 
oxygen therapy were reported during the trial period 
(data not shown).
Discussion
Use of tadalaﬁ l for 12 weeks did not improve exercise 
capacity, as measured by the 6 min walking distance. One 
possible explanation for this absence of eﬀ ect is that in 
the presence of mild pulmonary hypertension, exercise 
capacity is mainly limited by exhaustion of the ventilatory 
reserve.21,22 Of our three chosen quality-of-life measures, 
the St George’s Respiratory Questionnaire is the most 
relevant. We did not see an improvement in quality of life 
with 12 weeks of tadalaﬁ l treatment. The changes between 
groups in the activity and impacts score subdomains 
could mean that tadalaﬁ l might improve quality of life in 
a much larger study. However, if such an eﬀ ect was not 
apparent in the 113 patients in our study, the clinical 
relevance of any change in quality of life is questionable.
Tadalaﬁ l doses higher than 10 mg might be more 
eﬀ ective. At the time of our study design, tadalaﬁ l had not 
been licensed for pulmonary hypertension at the present 
daily 40 mg dose that has since become the accepted 
starting dose for patients with idiopathic pulmonary 
arterial hypertension.8 Our dose selection was informed 
by the anticipated pharmacokinetics in our elderly 
population by contrast with those in younger patients with 
idiopathic pulmonary arterial hypertension. The half-life 
of tadalaﬁ l is increased (from 17·5 to 21·6 h) and clearance 
is also signiﬁ cantly reduced in elderly people.23,24 
Information from the Electronic Medicines Compendium 
states that a dose adjustment in elderly patients is not 
warranted; however, this recommendation is based on 
data in healthy patients and not in those with severe 
COPD and pulmonary vascular disease—a largely 
unstudied population. In the absence of any data about 
the use of daily dosing with tadalaﬁ l in pulmonary 
hypertension, we drew inspiration from the successful 
treatment of erectile dysfunction, for which comparatively 
low single doses of tadalaﬁ l are used and daily dosing with 
10 mg or above was not recommended. Furthermore in 
the pivotal randomised trial by Galiè and colleagues,8 
10 mg, 20 mg, and 40 mg dosing of tadalaﬁ l at 12 weeks 
seemed to be equally eﬀ ective for improvement of 6 min 
walking distance, although only the 40 mg dose was 
associated with a signiﬁ cant increase in walking distance 
and prolonged time to clinical worsening at 16 weeks.By 
contrast with our own treatment-naive study population, 
more than 50% of the patients in Galiè and colleagues’ 
trial were receiving bosentan, which because of interaction 
with cytochrome P450 3A4 could necessitate high doses to 
be eﬀ ective. Our chosen dose (10 mg) of tadalaﬁ l caused 
the expected pulmonary vasodilatation with no eﬀ ect on 
6 min walking distance.
We noted signiﬁ cant increases in pulmonary 
acceleration time in patients in the treatment group, only 
Figure 3: Eﬀ ects of one 50 mg dose of sildenaﬁ l on SpO2 over time
n=120. SpO2=peripheral oxygen saturations. 
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in keeping with a small reduction in pulmonary vascular 
resistance and pulmonary pressure, the latter of which 
we estimated to be 3·5 mm Hg.13,25 This ﬁ nding supports 
those from other published work showing that after 
3 months of sildenaﬁ l, the pulmonary acceleration time 
was the only echocardiographic parameter to change 
signiﬁ cantly in line with other well-established right-
heart catheter measures (mean pulmonary artery 
pressure and pulmonary vascular resistance).26 Acute 
sildenaﬁ l dosing decreased SpO2 on the basis of 
ventilation perfusion mismatch, which increased blood 
ﬂ ow to poorly ventilated areas of the lung through release 
of hypoxic pulmonary vasoconstriction. This event was 
not apparent during chronic dosing with tadalaﬁ l despite 
evidence of pulmonary vasodilatation, possibly because 
of adaptive processes with chronic dosing, mitigating 
any regional ventilation perfusion mismatching.
One perceived limitation of our study is our considered 
decision to not undertake right-heart catheterisation for 
patient selection and assessment of treatment response. 
We ruled out right-heart catheterisation for both logistical 
(distance of travel for patients and need for hospital 
admission) and ethical reasons, in that repeated 
catheterisation poses a small but unacceptable risk to 
patients, particularly because consideration of 
catheterisation is not routine practice in patients with 
COPD with suspected borderline or mild pulmonary 
hypertension. Although other studies in this specialty 
have suggested use of pulmonary vasodilator drugs on 
the basis of the high prevalence of exercise-induced 
pulmonary hypertension in patients with severe COPD, 
we wished to further characterise our participants with 
echocardiography.10,11 Almost all the participants in our 
study had a measurable pulmonary acceleration time; as 
such, acceleration time is the key echocardiography 
parameter deﬁ ning our cohort. Echocardiography-
derived pulmonary acceleration time and pulmonary 
acceleration time to right ventricular ejection time ratio 
have an excellent correlation (r –0·88 to –0·90) with right 
catheter-derived mean pulmonary arterial pressure.13,27 
This technique is advantageous in the assessment of 
patients with pulmonary hypertension who are poorly 
echogenic, particularly when the discordance between 
right ventricular systolic pressure and invasive catheter 
measures is considered.28 Although a precise estimation 
of mean pulmonary arterial pressure cannot be derived 
from pulmonary acceleration time, our methods were 
chosen to be a simple, reliable way to stratify participants. 
Use of all available echocardiographic methods and not 
solely the right ventricular systolic pressure has been 
emphasised in a debate of pros and cons.29
Another potential limitation is our use of fairly modest 
indicators of pulmonary vascular disease for assessment 
of inclusion in the study, at the risk of including patients 
without pulmonary hypertension. Even mild increases in 
pulmonary pressure, not presently considered to 
represent pulmonary hypertension, can result in clinically 
signiﬁ cant changes to the structure and function of the 
right heart.5 Our selection criteria of a pulmonary 
acceleration time less than 120 ms was chosen to include 
all patients with a mean pulmonary arterial pressure of 
greater than 16 mm Hg. The estimated mean pulmonary 
arterial pressure in our ﬁ nal cohort and the proportion of 
patients with right-ventricular dilation are consistent with 
a degree of pulmonary vascular disease. Although the 
upper range for right ventricular systolic pressure and the 
lower range for pulmonary acceleration time suggest the 
inclusion of those with severe pulmonary hypertension, 
small numbers preclude any conclusions about the 
eﬀ ectiveness of tadalaﬁ l in participants with more severe 
pulmonary hypertension. Tadalaﬁ l could still conceivably 
improve exercise capacity in individuals with more severe 
pulmonary hypertension or mild airﬂ ow obstruction—a 
comparatively rare subgroup in whom further study is 
warranted.
Most studies of COPD that include measures of right-
heart catheterisation naturally represent highly selected 
groups of patients with COPD who are referred to tertiary 
centres for consideration of lung transplant, surgery for 
reduction of lung volume, or investigation of dis-
proportionate or severe pulmonary hypertension. In our 
cohort, the lack of clinical improvement with tadalaﬁ l, 
despite enrichment of the study population through 
echocardiography, suggests that PDE5 inhibitors do not 
improve exercise capacity and quality of life in patients 
with moderate to severe COPD, even if there is a 
Panel 2: Research in context
Systematic review
We searched PubMed betweeen Jan 1, 1980, and Jan 1, 2014, for “phosphodiesterase-5 
inhibitors”, “tadalaﬁ l”, “sildenaﬁ l”, “COPD”, “pulmonary hypertension”, “pulmonary 
arterial hypertension”, “exercise tolerance”, and “exercise capacity”. Our review of the 
existing literature emphasised the scarcity of robust evidence for or against the use of 
phosphodiesterase-5 (PDE5) inhibitors in patients with pulmonary hypertension 
associated with chronic obstructive pulmonary disease (COPD). We identiﬁ ed only two 
randomised trials. In the ﬁ rst,11 in patients with COPD and emphysema, but without 
pulmonary hypertension, sildenaﬁ l had no eﬀ ect on exercise capacity and worsened 
quality of life. The second trial30 showed that sildenaﬁ l in addition to pulmonary 
rehabilitation did not confer an additional improvement in exercise tolerance in patients 
with severe COPD and mild to moderate pulmonary hypertension.
Interpretation
Our ﬁ ndings suggest that in patients with moderate to severe COPD, selected to have 
borderline to mild pulmonary hypertension, tadalaﬁ l does not improve exercise capacity or 
quality of life. This outcome is in keeping with evidence from randomised trials suggesting 
that in patients with COPD with emphysema and no pulmonary hypertension, or in those 
with COPD and mild to moderate pulmonary hypertension undertaking pulmonary 
rehabilitation, sildenaﬁ l does not improve exercise capacity or quality of life. Our ﬁ ndings 
therefore discourage use of PDE5 inhibitors in patients with moderate to severe COPD and 
borderline to mild pulmonary hypertension as a means to improve exercise capacity and 
quality of life. Further trials should focus on comparatively rare subgroups such as individuals 
with severe pulmonary hypertension or mild airﬂ ow obstruction, whereby PDE5 inhibitors 
could still conceivably have beneﬁ cial eﬀ ects.
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suggestion of pulmonary hypertension on echocardio-
graphy. This message is timely because sildenaﬁ l is no 
longer patented and is available on a generic tariﬀ . Our 
ﬁ ndings are consistent with the work of Blanco and 
colleagues30 in which sildenaﬁ l did not further improve 
exercise capacity in participants undergoing pulmonary 
rehabilitation, based on a cohort with echocardiography-
deﬁ ned pulmonary hypertension and, to a lesser extent, 
hypertension conﬁ rmed by right-heart catheterisation. 
Our study diﬀ ers in its primary assessment of exercise 
capacity and has been powered accordingly, necessitating 
double the participants. Our complementary ﬁ ndings 
strengthen the case against the indiscriminate use of 
PDE5 inhibitors in COPD patients with borderline or 
mild pulmonary hypertension (panel 2).
In what represents a large cohort of patients with 
COPD and mild pulmonary hypertension we have shown 
that tadalaﬁ l at a dose of 10 mg per day does not improve 
exercise capacity despite exerting its pharmacological 
eﬀ ect of pulmonary vasodilation.
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